Argenx SE starts the week with a full trial pipeline, shares watched by biotech investors

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 07:26.

Argenx SE (NL0010832176) starts the new week with a busy clinical program around its autoimmune portfolio, led by the FcRn blocker Vyvgart. The biotech company trades on NASDAQ, where its shares remain closely followed by sector specialists and generalist investors.

Clinical pipeline and Vyvgart focus

Argenx SE operates a broad pipeline of antibody-based therapies for autoimmune diseases, with Vyvgart (efgartigimod) as its first approved product. The drug targets the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies in conditions such as generalized myasthenia gravis, a strategy documented in company clinical data and presentations. Argenx investor materials outlining Vyvgart and the pipeline

The company has multiple ongoing Phase 3 and Phase 2 trials that extend Vyvgart into additional autoimmune indications, including immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy, according to its latest pipeline overview and regulatory filings. These studies underpin growth expectations embedded in current analyst models and are a key reason why Argenx is frequently discussed among leading mid-cap biotech names alongside peers such as Horizon Therapeutics and Incyte in sector commentary. FierceBiotech reporting on Argenx clinical plans

Analyst consensus and NASDAQ listing

Analyst coverage of Argenx SE is broad, with banks such as Goldman Sachs, JPMorgan and Jefferies following the stock as part of their biotech universes. Consensus data compiled on financial portals show a clear majority of Buy or Outperform ratings and price targets that reflect expectations for continued Vyvgart uptake and pipeline progress, even though individual targets differ and are regularly updated after major trial or regulatory milestones. MarketScreener overview of Argenx analyst consensus

Argenx SE shares trade on NASDAQ in the United States, giving the company access to deep biotech investor pools and liquidity that is typical for innovative drug developers. The NASDAQ listing also makes the stock sensitive to broader moves in biotech indices and growth shares, with performance often compared against sector benchmarks such as the Nasdaq Biotechnology Index and peers active in autoimmune and rare disease therapies. NASDAQ price and listing data for Argenx shares

How Argenx makes its money

Argenx SE generates revenue primarily from sales of Vyvgart, its antibody fragment therapy for generalized myasthenia gravis, and from collaboration income with partners on selected programs. As Vyvgart expands into new indications and geographies, product revenue is expected to become an increasingly central driver of the company's top line alongside potential milestone payments from partnered assets.

Where the stock trades today

Argenx SE shares are listed on NASDAQ in the United States; the latest available trading data show the stock quoted in US dollars during regular US market hours.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.